news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

influenced by the news of expanding the pilot opening-up in the medical field, hainan haiyao (000566) continued its strong trend on september 9, achieving two consecutive gains, and the latest closing price was 3.71 yuan per share, with a market value of 4.813 billion yuan.

on the evening of september 9, hainan haiyao issued an announcement on unusual stock price movements, responding positively to hot topics of concern to the market, stating that its shareholding company unicore is mainly engaged in human somatic cell preparation, storage, applied technology research and drug development, but it has been in the stage of r&d investment and market development, and has not yet achieved profitability. there are also uncertainties in future related products in terms of technology research and development, competitiveness, etc.

on the same day, hainan haiyao disclosed the impact of super typhoon makar no. 11: after the typhoon, some of the company's buildings, factories, inventory, and landscaping were damaged to a certain extent. after rescue and self-rescue, the disaster did not cause casualties, and the asset loss is expected to be no more than 15 million yuan. at present, the company's production and operation activities have basically returned to normal.

on the news front, the ministry of commerce, the national health commission, and the national medical products administration recently issued a notice on expanding the pilot work of opening up in the medical field, proposing that foreign-invested enterprises be allowed to engage in the development and application of human stem cells, gene diagnosis and treatment technologies in the china (beijing) pilot free trade zone, china (shanghai) pilot free trade zone, china (guangdong) pilot free trade zone, and hainan free trade port for product registration, listing, and production. all products that have been registered, listed, and approved for production can be used nationwide.

hainan haiyao is mainly engaged in the research and development, production and sales of drugs and medical devices. its main products are antibiotics, gastrointestinal drugs, anti-tumor drugs, apis and intermediates supporting preparations and other products. in recent years, in addition to the chemical medicine sector, the company has actively explored the field of biopharmaceuticals and entered the field of cell therapy when the opportunity arose, enriching its industrial layout and product structure. investing in unicol is one of them.

currently, hainan haiyao holds a 35% stake in unicore. it is reported that unicore is registered in xiuying district, haikou city, hainan province. its business scope includes stem cell research, cell preparation, stem cell storage, immune cell storage, etc. it has three functional units: cell tissue bank, cell preparation center and regenerative medicine research center. in recent years, although unicore's revenue has maintained rapid growth, it has not yet achieved profitability.

in terms of main business, hainan haiyao has many products with leading market share. according to the sample hospital data of the chinese pharmaceutical association (cpa), the company's fengliao changweikang granules will have a market share of 56% in 2023, ranking first in china, cefuroxime sodium will have a market share of 10.6% in 2023, ranking second in china, and cefuroxime sodium will have a market share of 15.9% in 2023, ranking second in china.

in the first half of this year, the pressure on pharmaceutical sales continued to increase, and hainan haiyao's revenue and net profit both declined, recording a revenue of 593 million yuan, a year-on-year decrease of 38.16%; a net profit loss of 200 million yuan, a year-on-year change from profit to loss. in terms of breakdown, the company's pharmaceutical business revenue was 500 million yuan, a year-on-year decrease of 41.97%, accounting for 84.34% of the total revenue, and the gross profit margin of the sector was 36.4%, a year-on-year decrease of 3.62 percentage points; medical service revenue was 77.2309 million yuan, a year-on-year decrease of 10.49%, accounting for 13.01% of the total revenue, and the gross profit margin of the sector was 12.72%, a year-on-year decrease of 2.17 percentage points.

regarding the market development plan for 2024, hainan haiyao stated that it will focus on developing the second, third, and fourth terminals, vigorously develop chain pharmacies, primary medical institutions and e-commerce businesses, and take chinese medicine varieties as key incremental varieties. by integrating varieties, policies, and channels, it will achieve the expansion and solidification of the incremental market.